Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Top Cited Papers
- 1 February 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (2) , 130-140
- https://doi.org/10.1038/nrc1801
Abstract
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) show indisputable promise as chemopreventive agents. Possible targets include cancers of the colon, stomach, breast and lung. However, recent studies raise concern about potential cardiovascular toxicity associated with the use of NSAIDs that specifically target the enzyme cyclooxygenase 2. These findings, and others that show that inherited genetic characteristics might determine preventive success, argue for new strategies that are tailored to individual medical history and genetic make-up.Keywords
This publication has 137 references indexed in Scilit:
- Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal CancerJAMA, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- Inflammation and cancerNature, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- APC mutations occur early during colorectal tumorigenesisNature, 1992